Special Issue

Metabolomics and Biomarker Discovery and Evaluation: The New Frontier in the Screening, Diagnosis and Therapeutic Monitoring of Inborn Errors of Metabolism

Message from the Guest Editor

In this Special Issue of *Metabolites* we welcome research proposals which include but are not limited to the following topics:

- Metabolomics techniques and approaches for clinical purposes;
- Targeted vs. untargeted metabolomics in inborn errors of metabolism;
- Biomarker discovery and validation for the screening and diagnosis of inborn errors of metabolism;
- Biomarker discovery and validation for the therapeutic monitoring of inborn errors of metabolism;
- Phenotype correlation with novel biomarkers in inborn errors of metabolism;
- Genotype correlation with novel biomarkers in inborn errors of metabolism;
- Genetics vs. metabolomics for the screening of inborn errors of metabolism.


Guest Editor

Dr. Mohamed A. Elmonem

Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo 11628, Egypt

Deadline for manuscript submissions

closed (20 December 2023)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed

mdpi.com/si/127872

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed

mdpi.com/journal/ metabolites

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

